Funded Projects

Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.

Reset
Project # Project Title Research Focus Area Research Program Administering IC Institution(s) Investigator(s) Location(s) Year Awarded
1R21DA060111-01
The potential benefits of autophagy activator TFEB in opioid use disorder in mice Novel Therapeutic Options for Opioid Use Disorder and Overdose NIDA FLORIDA INTERNATIONAL UNIVERSITY LAKSHMANA, MADEPALLI KRISHNAPPA Miami, FL 2024
NOFO Title: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-23-010
1R21DA060304-01A1
Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trial Novel Therapeutic Options for Opioid Use Disorder and Overdose NIDA BRIGHAM AND WOMEN'S HOSPITAL SUZUKI, JOJI Boston, MA 2024
NOFO Title: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
NOFO Number: PA-20-194
4UH3DA047793-03
tDCS to Decrease Opioid Relapse Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA BUTLER HOSPITAL ABRANTES, ANA M (contact); STEIN, MICHAEL D Providence, RI 2024
NOFO Title: Device-Based Treatments for Substance Use Disorders (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-18-494
4UH3DA054825-03
A novel and highly selective orexin 1 receptor antagonist for the treatment of patients with opioid use disorder. Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA ASTRAZENECA PHARMACEUTICALS, LP GURRELL, IAN Wilmington, DE 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
NOFO Number: PAR-20-092
1UG3DA060053-01
Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA GILGAMESH PHARMACEUTICALS, INC. MAREK, GERARD JOSEPH New York, NY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1UG3DA059278-01A1
Development of SBS-226, a MOR agonist / DOR antagonist, for OUD Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA SPARIAN BIOSCIENCES, INC. REICH, JEFFREY New York, NY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1UG3DA061620-01
Registration Development Program for LUCEMYRA (Lofexidine) Label Expansion for Opioid Withdrawal Treatment in Adolescents Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA USWM, LLC MASSEY, VERONICA LYNCH (contact); SCHMIDT, LEE Louisville, KY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200
1U01DA059994-01
Efficacy, safety, and pharmacokinetic study of BICX104 naltrexone subcutaneous implant alone and in combination with bupropion for the treatment of Methamphetamine Use Disorder (MUD). Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA BIOCORRX PHARMACEUTICALS, INC. DEVARNEY, KATE BEEBE Anaheim, CA 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1U01DA060708-01
Phase III double-blind, randomized controlled trial of suvorexant versus placebo to treat insomnia in persons with opioid use disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA JOHNS HOPKINS UNIVERSITY HUHN, ANDREW S Baltimore, MD 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1U01DA059791-01A1
PF614-MPAR: clinical development of opioid with oral overdose protection Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA ENSYSCE BIOSCIENCES, INC. KIRKPATRICK, LYNN La Jolla, CA 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1U01DA060704-01A1
Development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER FRANCE, CHARLES P San Antonio, TX 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
1U01DA061643-01
Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA NIRSUM LABORATORIES, INC. SHAH, NIKEJ (contact); SORENSON, MARK New York, NY 2024
NOFO Title: Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
NOFO Number: PAR-22-202
4UH3DA048767-03
Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA EICOSIS, LLC CORTES-PUCH, IRENE (contact); HAMMOCK, BRUCE D Davis, CA 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
NOFO Number: RFA-DA-19-002
1UG3DA061616-01
Deep TMS Neuromodulation of Neural Circuits Associated with Stimulant Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose NIDA STANFORD UNIVERSITY PADULA, CLAUDIA B (contact); MADORE, MICHELLE ROSEANN Redwood City, CA 2024
NOFO Title: Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
NOFO Number: PAR-23-253
1UG3DA062106-01
Targeting Treatment-Resistant OUD with Ketamine-Assisted Mindfulness-Oriented Recovery Enhancement Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF UTAH GARLAND, ERIC LEE (contact); NUNES, EDWARD V Salt Lake City, UT 2024
NOFO Title: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
NOFO Number: RFA-DA-25-058
1UG3DA062088-01
Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA NEW YORK UNIVERSITY SCHOOL OF MEDICINE BOGENSCHUTZ, MICHAEL PARKS New York, NY 2024
NOFO Title: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional)
NOFO Number: RFA-DA-25-058
1R21DA062022-01
Neuropeptide S Receptor 1 as a Novel Target for Reducing Opioid Self-Administration and Opioid Relapse Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER TUNSTALL, BRENDAN Memphis, TN 2024
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-24-064
1R21DA061784-01
Preclinical Trial: Targeting the Neuropeptide S Receptor to Curb Opioid Taking and Seeking Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA STATE UNIVERSITY OF NEW YORK AT BUFFALO CLARK, STEWART DONALDSON Amherst, NY 2024
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-24-064
1R01DA061771-01
Pharmacological targeting of nascent modulators of opioid signaling Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF FLORIDA MARTEMYANOV, KIRILL A Gainesville, FL 2024
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-24-063
1R01DA061773-01
Neurotensin receptor 1 as a novel target for opioid use disorder and discovery of new small molecule probes Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA UNIVERSITY OF MINNESOTA SLOSKY, LAUREN M (contact); OLSON, STEVEN H Minneapolis, MN 2024
NOFO Title: HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DA-24-063
4UH3DA048338-03
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA DRUG DELIVERY COMPANY, LLC COHEN, STEVEN M (contact); BENNER, JEFFREY Salisbury, MD 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
NOFO Number: RFA-DA-19-002
4UH3DA050323-02
Cannabidiol in the treatment of opioid use disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI HURD, YASMIN L New York, NY 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
NOFO Number: RFA-DA-19-002
4UH3DA050325-03
Use of a GLP-1 Agonist to Treat Opioid Use Disorder in Rats and Man Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA PENN STATE HEALTH HERSHEY MEDICAL CENTER GRIGSON, PATRICIA SUE (contact); BRICK, TIMOTHY R; BUNCE, SCOTT C; NYLAND, JENNIFER E Hershey, PA 2024
NOFO Title: Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trials Optional)
NOFO Number: RFA-DA-19-002
1R01DE033318-01
Understanding the Association Between Sublingual Buprenorphine and Oral Health Outcomes Novel Therapeutic Options for Opioid Use Disorder and Overdose Oral Complications Arising From Pharmacotherapies to Treat Opioid Use Disorders NIDCR UNIVERSITY OF KENTUCKY ROJAS RAMIREZ, MARCIA VANESSA (contact); OYLER, DOUGLAS Lexington, KY 2023
NOFO Title: HEAL Initiative: Oral Complications Arising from Pharmacotherapies to Treat Opioid Use Disorders (R01 Clinical Trial Not Allowed)
NOFO Number: RFA-DE-23-015
Summary:

Sublingual buprenorphine is a standard treatment for opioid use disorder and is considered safe and effective. However, in 2022 the U.S. Food and Drug Administration advised that buprenorphine is linked to oral disease. However, the underlying studies did not measure when oral disease started, how it progressed, or if other risk factors were present. How sublingual buprenorphine may impact oral health also remains unclear. This project will follow adults in two U.S. states who take sublingual buprenorphine or other medications for opioid use disorder to understand if and how these medications increase the extent, onset, and progression of oral disease, accounting for other risk factors.
1UG3DA058544-01A1
Antibody-based therapy for fentanyl-related opioid use disorder Novel Therapeutic Options for Opioid Use Disorder and Overdose Focusing Medication Development to Prevent and Treat Opioid Use Disorder and Overdose NIDA MCLEAN HOSPITAL DESAI, RAJEEV INDRAJIT (contact); BREMER, PAUL T Belmont, MA 2023
NOFO Title: Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
NOFO Number: PAR-22-200